Owlstone Medical, the innovative company which promises to revolutionise the diagnosis of cancer by simply analysing a patient's breath has been given a major funding boost.
One of the UK’s most promising medtech start-ups, Owlstone Medical has been given a major boost by GSK’s decision to include its technology in a major clinical trial programme.
The venture capital arm of the UK’s biggest insurance firm Aviva is to invest $5 million (£4m) in Owlstone Medical, one of the country’s most promising and potentially groundbreaking diagno